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Abstract
The objective of these studies was to characterize the IL-1 in-
hibitory activity present in normal and psoriatic epidermis from
clinically stable lesions. Fractionation of normal epidermal cy-
tosol on a molecular sizing column failed to reveal the presence
of IL-1 inhibitory bioactivity. However, specific ELISAs indi-
cated that both the IL-1 receptor antagonist (IL-lra) and IL-
la were present in overlapping peaks. Further fractionation of
the normal epidermal cytosol by anion exchange chromatogra-
phy separated these two molecules, revealing the IL-1 inhibi-
tory bioactivity ofthe IL-lra molecule. Similar studies on psori-
atic epidermal cytosol indicated the presence of IL-1 inhibitory
bioactivity and IL-lra protein. The IL-1 inhibitory bioactivity
of both normal and psoriatic cytosol was neutralized by a mAb
specific for IL-lra. The ratio of IL-lra to IL-la proteins was
significantly increased in involved psoriatic skin compared with
normal skin. By Western blot analysis this IL-lra was 20
kD, slightly larger than monocyte-derived IL-lra and equiva-
lent to an intracellular variant of IL-lra expressed by keratino-
cytes. Polymerase chain reaction indicated the presence of
mRNA for both forms of IL-lra in normal epidermis, with both
forms increased in psoriatic-involved skin. Immunofluores-
cence studies revealed the IL-lra protein to be concentrated in
the stratum granulosum ofnormal skin and in the basal-midba-
sal layers of psoriatic epidermis. These results suggest that the
balance between intracellular IL-lra and IL-la may be an im-
portant influence on keratinocyte growth and/or differentia-
tion, as well as on the inflammatory potential of IL-1 in injured
skin. (J. Clin. Invest. 1992. 90:571-583.) Key words: IL-lia
IL-1if * homeostasis * differentiation - keratinocyte
Introduction
The skin is a major reservoir of IL- I ( 1, 2) because ofconstitu-
tive production by keratinocytes (3, 4) and sweat gland epithe-
lium (5). IL- I is capable of inducing cutaneous inflammation
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upon injection into human skin (6) and is released from the
epidermal cells after ultraviolet (UV) radiation (7-9). Epider-
mal IL-I release not only recruits an inflammatory response,
but also potentiates T cell subset activation and the nature of
the subsequent inflammatory response (10). The mechanisms
by which the inflammatory potential of the large amounts of
IL-i contained in the epidermis are restrained may be due in
part to the inability of keratinocytes to effectively proteolyse
inactive IL- I # precursor molecules ( 11 ), such that human epi-
dermis contains inactive IL- I, that has been processed into
novel informs of the molecule ( 12). IL-I a, which is active in
vivo in both the precursor and processed forms, remains intra-
cellular in unstimulated keratinocytes (13). Thus, the role of
IL- I in skin and its regulation in cutaneous homeostasis in vivo
remain poorly understood.
A skin condition that may provide clues to the involvement
of IL-I in skin biology is psoriasis. IL-I has the ability to cause
cutaneous inflammation (6), potentiate T cell activation ( 14),
stimulate eicosanoid metabolism ( 15), induce fibroblast prolif-
eration ( 16), upregulate endothelial cell adhesion molecule ex-
pression ( 17, 18), and potentially stimulate keratinocyte prolif-
eration ( 19, 20). Because each of these elements may be pres-
ent in psoriatic skin (21-28), overexpression of IL-I has been
postulated as a possible trigger for this disease process. How-
ever, the growth-promoting capacity of IL-I for human kera-
tinocytes has been called into question (29) and IL- I activity is
markedly reduced in psoriatic skin (30). Despite existing in a
processed form, epidermal IL-1I, was incapable of activating a
murine T cell line expressing the type I IL-I receptor or of
activating murine thymocytes (30). The nonfunctionality of
the IL- I1, in concert with a 14-fold decrease in IL- I a levels are
consistent with the reduced levels of IL-I activity in psoriatic
keratome extracts (30). Further complexity was added to the
situation on finding that an inhibitor of IL- I activity also con-
tributed to the markedly reduced bioactivity of IL-I in psori-
atic lesions (30). This inhibitor was not secreted constitutively,
had a molecular mass of - 30 kD and an isoelectric point of
5.3 and was distinct from transforming growth factor (3
(TGF3) ' (3 1 ).
Recently, a specific human IL-I receptor antagonist (IL-
I ra) has been purified from the supernatants ofIgG-stimulated
monocytes (32) and from the myelomonocytic leukemia cell
line U937 after induction of differentiation (33). The IL-Ira
molecule was sequenced and is a single peptide of 152 amino
acids that exists in both 1 7-kD nonglycosylated and 22-25-kD
1. Abbreviations used in this paper. DPBs, Dulbecco's modified PBS;
FPLC, fast protein liquid chromatography; IL- I ra, interleukin- I recep-
tor antagonist; PCR, polymerase chain reaction; TGFB, transforming
growth factor,.
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glycosylated forms with a pI of 5.0 (32, 33). IL-Ira has 30%
amino acid sequence homology to IL-I,8 and 19% homology to
IL-Ia. Complementary DNAs have been cloned and expressed
in Escherichia coli with production of recombinant 1 7-kD IL-
Ira molecules that retain full biological activity (32-34). IL-
Ira appears to be a true receptor antagonist in that it competi-
tively binds to the type I IL-i receptor on T cells (32, 33),
endothelial cells (33), fibroblasts (32), synovial cells, and
chondrocytes (35) and the human type II IL-i receptor on B
cells and polymorphonuclear leukocytes (36, 37) without in-
ducing detectable cellular responses.
The mRNA for a structural variant of monocyte-derived
IL-Ira has recently been described in cultured keratinocytes
and other epithelial cells (38). The cDNA clones derived from
both monocytes and cultured keratinocytes predict that this
mRNA encodes for a protein that is identical to mature 1 7-kD
monocyte IL- Ira except for the presence ofan additional seven
NH2-terminal amino acids and the lack of a leader peptide for
secretion. Cultured keratinocytes produce a large quantity of
IL-Ira that remains entirely intracellular (icIL- Ira) and is
slightly larger in size than 1 7-kD monocyte IL- Ira protein (sIL-
ira) (38, 39). IL-Ira production by cultured keratinocytes in-
creases with cell differentiation (39).
The purpose of the present studies was to examine freshly
obtained human skin from normal subjects to determine
whether IL- Ira is produced in vivo by epidermal keratinocytes.
Furthermore, we wanted to determine if the IL-I inhibitory
activity that dominates in psoriatic epidermis could be attrib-
uted to expression of IL-Ira. Cytosolic extracts of keratome
biopsies were fractionated by both gel filtration and ion ex-
change chromatography. The fractions were analyzed for IL- I
inhibitor bioactivity, both IL- Ira and IL- I a proteins by specific
ELISAs, and neutralization of functional activity with specific
antibodies. In addition, IL-Ira was localized in intact skin by
immunofluorescence techniques and the presence of mRNA
transcripts within the epidermis were identified by polymerase
chain reaction (PCR). Our results raise the possibility that IL-
Ira is important for cutaneous homeostasis not only by limit-
ing the inflammatory effects of extracellular IL-I in injured
skin, but also by limiting putative intracellular actions of IL- 1.
Methods
Materials. Polyethylene glycol (PEG, mol wt 8,000), sucrose,
Tris, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,
MOPC2 1, Tween 20, and PMSF were obtained from Sigma Chemical
Co. (St. Louis, MO). PHA was obtained from Wellcome Diagnostics
(Dartford, England). DTT was purchased from Bio-Rad Laboratories
(Rockville Center, NY). The Fast Protein Liquid Chromatography
(FPLC) apparatus and Mono Q anion exchange column were pur-
chased from Pharmacia Inc. (Piscataway, NJ). A TSK G2000SW mo-
lecular sizing column was obtained from Toyo Soda (Tokyo, Japan). A
rabbit antiserum and a mAb to IL- Ia used in the ELISA and human
recombinant IL- Ia were gifts from Dainippon Pharmaceutical Corp.
(Osaka, Japan). Human recombinant IL-1,# was purchased from Cis-
tron Corp. (Pine Brook, NJ). Rabbit polyclonal antiserum to IL-Ira
was prepared and characterized as previously described (32, 40). Hy-
bridomas secreting mAbs to the IL- Ira protein were derived using de-
scribed techniques (41 ). The spleen cell donors were CAF, mice that
had been injected four times with 5-20 ,ug purified or recombinant
IL-Ira. None of the resulting mAbs, 1.4, 1.5 and 1.10, reacted with
human IL- la or IL- I,3 in ELISAs. These mAbs and the human recom-
binant IL-Ira protein were provided by The Upjohn Company. The
mAb to TGFl was obtained from Collagen Corp. (Palo Alto, CA).
Peroxidase-conjugated goat anti-rabbit IgG antibodies, goat anti-
mouse IgG-biotin conjugate and goat anti-mouse IgG rhodamine-B
conjugate were obtained from Tago Inc. (Burlingame, CA). Streptavi-
din-horseradish peroxidase conjugate was from Bethesda Research
Laboratories (Gaithersburg, MD). Keratinocyte culture medium
(modified MCDB 153) was formulated as described (42).
Preparation ofkeratome and keratinocyte cytosols. Keratome biop-
sies were obtained from lesional psoriatic plaques, clinically unin-
volved psoriatic skin, and skin ofnormal subjects. Patients with psoria-
sis in this study had clinically stable plaques of sufficient size to enable
two 10-cm2 strips to be biopsied. The patients were off active therapy
(except for bland emollients) for 2 1 wk before the biopsy. The biop-
sies from both normal and psoriatic skin were performed on the hips or
buttocks using a Castro Viejo keratome set (Storz Co., St. Louis, MO)
at 0.2-0.3 mm. Keratome strips were immediately snap frozen in liq-
uid nitrogen. Keratomes were pulverized under liquid nitrogen. Dul-
becco's PBS (DPBS, Ca++- and Mg"+-free) with 1 mM PMSF and
0.03% PEG was added at 100 mg keratome wet wt/ml buffer for sam-
ples to be examined by FPLC; DPBS plus 5 mM DTT were added if
cytosolic IL- 1 ra and IL- 1 a levels were to be measured directly in an
ELISA. After homogenization with a glass homogenizer, cytosols were
obtained by ultracentrifugation (100,000 g, 60 min) and the superna-
tants were sterile filtered and stored at -70'C.
Cytosols were prepared from cultured adult human keratinocytes
grown from keratomes in modified MCDB 153 by washing the mono-
layer three times with HBSS (Ca++- and Mg++-free) and then scraping
the cells offin the presence ofDPBS with 1 mM PMSF and 0.03% PEG.
After three cycles of freeze thawing, cells were sonicated, ultracentri-
fuged (100,000 g, 60 min), and the supernatant stored at -70°C. Pro-
tein concentrations of keratomes and cytosols were determined by a
protein assay kit (Bio-Rad Laboratories).
FPLC. 2 ml of keratome cytosol were applied to a TSK G2000SW
column equilibrated with DPBS plus 0.03% PEG. The flow rate was 3.0
ml/min and 2.0-ml fractions were collected. Each fraction was steril-
ized by passage through a 0.2-gm millipore filter and assayed for the
presence of IL- la protein, IL- I inhibitory activity, and IL- I ra protein.
Keratome cytosols were dialyzed against 0.025 M Tris (pH 7.6)
with 0.1% sucrose before application to a Mono Q column equilibrated
with 0.025 M Tris (pH 7.6) plus 0.1% sucrose. Samples were eluted
with a NaCl gradient ranging from 0 to 250 mM NaCl at a rate of 0.5
ml/min and l-ml fractions were collected. Fractions were dialyzed
against DPBS, then sterile filtered, and assayed for the presence of
IL-la protein, IL-I inhibitory activity, and IL-lra protein.
IL-Ia ELISA. Immunoreactive IL- la in samples was quantified by
using an ELISA as previously described (30). Standard curves of re-
combinant human IL-la ranging from 20 to 1,000 pg/ml were run for
each assay. The sensitivity of the IL-la ELISA was 10 pg/ml.
IL-1 inhibitor assay. IL-1 inhibitory activity was measured by
blocking the production of IL-2 by LBRM.33 cells in response to IL- I
and PHA as previously described (31 ). Keratome cytosols or fractions
from either the TSK G2000SW or Mono Q columns were tested for
IL- I inhibitory activity. Quantitation of the amount of IL- I produced
by LBRM.33 cells was made in relation to an IL-2 standard curve that
covered a range of 2-250 U/ml of activity. Maximal response of the
LBRM.33 sample was compared with the standard curve to obtain the
amount of IL-2 units per milliliter.
IL-Ira ELISA. IL-Ira protein was measured using a sandwich
ELISA recently described in detail (40). The primary antibody in this
ELISA was affinity-purified polyclonal rabbit antibodies specific for
IL-Ira. The secondary antibody was the IgG fraction ofthis antiserum
coupled to biotin, followed by streptavidin peroxidase conjugate and
2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic)acid (ABTS) solution.
The sensitivity ofthis ELISA was < 200 pg/ml and the ELISA failed to
recognize up to 100 ng/ml ofIL-la or IL-I P. The recombinant human
IL- Ira standard was provided by Dr. Robert C. Thompson, Synergen
Inc., Boulder, CO.
IL-Ira indirect immunofluorescence. mAbs to IL-Ira (1.4 and 1.10
ascites) or isotype control MOPC2 1 ascites were diluted 1:100 or 1:200
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and reacted with acetone-fixed 6-,gm sections of human skin-punch
biopsies frozen in O.C.T. compound (Miles Inc., Elkhart, IN) as previ-
ously described (43). To test whether soluble recombinant IL-Ira pro-
tein would inhibit the binding of mAbs to the skin sections, a 1:200
dilution ofantibody 1.4 was preincubated with recombinant IL-Ira ( 10
Mug) at 370C for 1 h. The antibody-antigen mixture was then centri-
fuged in a microfuge at 40C for 15 min and the supernatants were used
to react with the skin sections as described above.
IL-Ira neutralization assay. 50 Ml of mAb ascites against IL-Ira
(1.10, murine IgG, isotype) was added to 96-well flat-bottom tissue
culture plates and preincubated with 50 ,l ofTSK G2000SW or Mono
Q IL-l inhibitory fractions for 2 h at 370C. As an isotype control,
lD.l 16, an IgG1 murine mAb against TGF#1 (44), was added at the
same dilutions as mAb 1. 10.25 Ml ofPHA (2 Mg/well), LBRM.33 cells
(105 cells/well) and 50 ,l of rIL-lf (0.25 or 2.5 U/well) were then
added and incubated for 24 h at 37°C. The IL-I inhibitor assay was
then continued as described above.
Immunoblotting. Human epidermis or keratinocyte cytosol were
concentrated 5-10-fold with a Centricon 3 system (3,000 mol wt cut
off) (Amicon Division, W. R. Grace Co., Beverly, MA) and samples
were electrophoresed on a 12% SDS-PAGE gel and Western blotted as
described previously (43). After reaction with a mAb to IL- I ra (I.5 ) or
a myeloma isotype ascites control (MOPC 21), the nitrocellulose
membrane was reacted with a goat anti-mouse IgG biotin conjugate
followed by a streptavidin-horseradish peroxidase conjugate. The pres-
ence of the immune complex was detected using chemiluminescence
(ECL Western blotting detection system and Hyperfilm; Amersham
International, Arlington Heights, IL).
IL-ira mRNA in normal andpsoriatic skin. PCR was used to deter-
mine the presence ofmRNA for sIL- I ra, icIL- I ra, and IL- IB in normal
and psoriatic skin. Total RNA was prepared from normal and clini-
cally stable psoriatic keratomes by using RNAzol (Tel-Test, Inc.,
Friendswood, TX). Total RNA from monocytes was prepared as previ-
ously described (38). RNA was reverse-transcribed into-cDNA using
random hexamers as primers and PCR performed essentially as re-
ported (45). PCR primer pairs specific for icIL-lra and sIL-lra were
those used by Haskill et al. (38) and those for IL-1jI were described by
Wang et al. (46). A standard curve, which ranged from 14 to 0.014
pg/hl, was constructed for each PCR product using plasmid containing
a cDNA insert of the appropriate protein. PCR products were deter-
mined at 24, 26, and 28 cycles, but only data from 28 cycles are shown.
That the PCR products are from the correct sequence was confirmed
by repeating PCR upon the PCR products with primer pairs internal to
the original sequence. Ethidium bromide-stained gels were photo-
graphed on an UV light box with Polaroid type 55 positive/negative
film. The negative was rinsed in water, dried, and analyzed with a Laser
Densitometer (LKB Instruments, Gaithersburg, MD).
Statistical analysis. After log transformation of the ratio of IL-lra
and IL- la protein levels in the different samples, the mean ofthe indi-
vidual ratios ofthe involved psoriatic epidermis was compared with the
mean of the ratios of uninvolved psoriatic or normal epidermis by
univariate one-way analysis of variance.
Results
IL-i ra in normal epidermal cytosol. To determine whether IL-
1 inhibitory activity was present in in vivo epidermis ofnormal
skin, keratome cytosols were assayed for inhibition of IL-1I#
stimulation ofLBRM.33 cells. At a cytosol concentration of 3
,ug/ml, IL-1 activity was detected (Fig. 1). However, at a
higher cytosol concentration ( 13 ug/ml), IL-I activity disap-
peared. This result suggested the presence ofan IL- 1 inhibitor.
Indeed, when a suboptimal concentration of recombinant IL-
Il, was added to LBRM.33 cells in the presence of human
keratome cytosols, additive IL-1 bioactivity was observed at




















Figure 1. Both IL-l and IL-l inhibitory activities are present in kera-
tome cytosol from normal human skin. The data are expressed as
U/ml of IL-2 produced by LBRM.33 cells stimulated with normal
keratome cytosol in the presence or absence of a suboptimal concen-
tration of IL-1,8. The first bar indicates IL-l activity of 0.25 U/ml
IL- I# alone. Bars 2-4 show the detected levels of IL- I activity where
0.25 U/ml IL-1I8 was added to each of the indicated amounts of ker-
atome cytosol. Bars 5-7 indicate the levels of IL-l activity present
in the normal keratome cytosol alone.
duction ofIL-2 occurred at a keratome cytosol protein concen-
tration of 13 Mg/ml (Fig. 1). This finding suggests that either a
critical concentration of an IL-1-specific inhibitor must be
achieved to detect its function or that the keratome cytosols
contain a complex mixture of nonspecific and IL-1-specific
inhibitory and costimulatory factors.
To ascertain whether IL-Ira was present in the epidermal
cytosol, we used FPLC fractionation on a TSK G2000SW mo-
lecular sizing column to separate nonspecific inhibition from
IL-I-specific inhibitors. Although partial inhibition by a vari-
ety offractions was found, the presence ofIL-I inhibitory activ-
ity that could completely suppress the IL- I induction of IL-2
production by LBRM.33 cells was not revealed (Fig. 2 A).
However, when an ELISA specific for IL- I ra was performed on
the same fractions, IL- 1 ra protein was detected in fractions
coeluting at 30 kD (Fig. 2 B). Elution profiles ofELISA-de-
tectable precursor and processed forms ofIL-I a demonstrated
that both partially overlapped the IL-Ira peak, although they
eluted slightly before and after the IL-Ira protein, respectively
(Fig. 2 C). However, LBRM.33 cells are relatively insensitive
to the antagonist effect ofthe IL- I ra protein, a ratio in excess of
500:1 (IL- Ira:IL- 1 a) is required to obtain complete suppres-
sion of IL-I induction of IL-2 production (data not shown)
(33). Thus, the apparent absence of IL-I inhibitory biological
activity in the TSK G2000SW fractions may be due to the
presence of IL-i a molecules, which were also present in the
same fractions containing IL-I inhibitory activity (Fig. 2 C).
Because the presence of IL- I a in the same fractions as the
ELISA-detectable IL- I ra protein on gel-filtration chromatogra-
phy might mask IL- I inhibitory activity, cytosol from normal
epidermis was fractionated on an anion exchange Mono Q col-
umn (Fig. 3). This fractionation now clearly revealed the pres-
ence of IL- I inhibitory activity that eluted between 85 and 95
mM NaCl (Fig. 3 A). The peak of IL-I inhibitory activity co-
eluted with ELISA-detectable IL-Ira protein (Fig. 3 B). Addi-
tional ELISA-detectable IL-Ira protein was present in later
fractions without any corresponding IL-I inhibitory activity.
This result could be explained by the presence of small
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Figure 2. IL-la and IL-Ira proteins are both present in normal kera-
tome cytosol. The cytosol was fractionated by a FPLC TSK
G2000SW sizing column. Fractions were assayed for (A) IL-l inhibi-
torbioactivity (percent suppression of IL-l effects on LBRM.33
cells), (B) IL-lra protein (ng/ml by ELISA), and (C) IL-la protein
(pg/ml by ELISA).
amounts of IL- 1 a in these fractions eluting at high salt concen-
trations (Fig. 3 C). However, most of the IL- 1 a detectable by
ELISA eluted at NaCl concentrations (65-80 mM NaCl) lower
than those required for elution of the IL- lra. Only when the
IL-I a levels dropped below the limit of detection was IL- 1
inhibitory activity observed in fractions that contained ELISA-
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Figure 3. Fractionation of normal keratome cytosol by FPLC ion-ex-
change chromatography on a Mono Q column. A-C are described
in the Fig. 2 legend. The NaCl gradient (mM) is indicated on the right
ordinate.
fractions 19-25 would appear to be too high to allow detection
of IL- 1 inhibitory activity (Fig. 3 A) by the IL- lra protein
shown to be present in these fractions (Fig. 3 B).
IL-Ira in psoriatic epidermal cytosol. Unfractionated cyto-
sol from clinically stable psoriatic lesions displays a pattern of
IL- 1 inhibitory activity that differs from the pattern observed
in unfractionated cytosol from normal epidermis (Fig. 4). Un-











Figure 4. IL-I and IL-I inhibitory activities are present in keratome
cytosol from psoriatic-involved skin. The first bar indicates activity
of 0.25 U/ml IL-1 beta alone. Bars 2-4 indicate detected IL-i activity
where 0.25 U/ml IL- jI was mixed with the indicated concentrations
of psoriatic keratome cytosol. Bars 5-7 show the endogenous IL-I
activity in the keratome cytosol in the absence of added IL-If.
like normal cytosol, IL- I activity was observed in psoriatic cy-
tosol only at concentrations > 4 ,ug/ml. In addition, the IL-I
inhibitory activity at these higher concentrations was not com-
plete. These results again point toward a complex set ofinterac-
tions among cytokines with synergistic stimulatory action and
inhibitory action in crude unfractionated cytosols.
To determine whether IL- Ira is present in clinically stable
involved psoriatic epidermal cytosol, fractionations were per-
formed similar to those described for cytosols from normal
skin. In contrast to normal skin, size fractionation alone re-
vealed the presence of IL-I inhibitory activity (Fig. 5 A). In-
deed, as detected by ELISA, IL- Ira protein coeluted with IL- I
inhibitory activity in a major peak of 30 kD (Fig. 5 B). IL-I a
protein was only detected in a single fraction (Fig. 5 C), con-
firming that little IL-la was present in the psoriatic keratome
cytosol (30). The relative lack of IL-i a in the psoriatic frac-
tions (200 pg/ml in a single fraction) as compared to the abun-
dant amounts of IL-la in the normal fractions (400-2,800
pg/ml in nine fractions) likely accounts for the ease of detec-
tion of IL- I inhibitory activity in psoriatic cytosols.
To further characterize the IL- I inhibitors in psoriatic skin,
keratome cytosol from lesional epidermis was separated by an-
ion exchange chromatography. A large peak of IL- I inhibitory
activity eluted at a similar NaCl concentration (Fig. 6) as was
observed with normal skin (Fig. 3). The volume of ion-ex-
change fractions from the psoriatic skin cytosols was not suffi-
cient to permit performance of ELISAs for IL- I ra and IL- I a
proteins.
Epidermal IL-1 inhibitory activity is neutralizable by an
anti-IL-I raprotein mAb. To determine whetherthe IL- I inhibi-
tory activity that coeluted with the IL- I ra protein from normal
skin is indeed due to a functional IL-Ira molecule, antibody
neutralization ofthe Mono Q fractions ( 17 and 18) containing
IL-I inhibitory activity and ELISA-detectable IL-Ira protein
was performed (Table I). Addition of 0.25 U/ml of IL-i to
LBRM.33 cells resulted in release of 8.9 U/ml of IL-2. Addi-
tion of normal keratome cytosol fractions containing IL-I in-
hibitory activity (Mono Q fractions 17 and 18) resulted in
100% inhibition of LBRM.33 stimulation by IL-i (0 U/ml
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Figure 5. IL- I inhibitor bioactivity and IL- I ra protein are present in
involved psoriatic keratome cytosol. This cytosol was fractionated by
a TSK G2000SW sizing column and fractions analyzed for (A) IL-I
inhibitor bioactivity, (B) IL-Ira protein, and (C) IL-Ia protein.
protein at dilutions of 1:25 and 1:50 resulted in complete neu-
tralization of the IL-1 inhibitory activity as evidenced by the
release of 10.5 and 9.4 U/ml of IL-2, respectively. A mAb
isotype control, 1 D. 1 16, which is capable ofneutralizing TGFj3
activity, did not affect the IL- I inhibitory activity in these frac-
tions (0 units IL-2 release).
A similar result was obtained with MonoQ fractions 14, 15,
and 16 from involved psoriatic skin that contained IL-I inhibi-
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Figure 6. Fractionation of involved psoriatic keratome cytosol by
FPLC ion exchange chromatography on a Mono Q column. The left
ordinate depicts the percent suppression of IL-2 production by IL- l-
induced LBRM.33 cells; the right ordinate shows the NaCl gradient
in mM, and the abscissa represents the column fractions. The hori-
zontal line indicates 0% suppression of IL- I bioactivity; all data points
above this line represent inhibition of IL- I activity.
tory activity. In this experiment addition of0.25 U/ml ofrIL- I
resulted in the release of 16.9 U/ml IL-2 and this response was
completely blocked by psoriatic cytosol (Table I). The IL-1
inhibitory activity of these fractions was completely neutral-
Table I. Monoclonal Antibody to IL-ira Neutralizes IL-i
Inhibitory Activity in Pooled Mono Q Fractions
Addition to LBRM.33 cells and PHA IL-2 released* IL-I inhibitiont
U/mi % suppression
IL- 1 8.9
IL- 1 + normal keratome fractions 0 100%
IL-l + normal cytosol
+ anti-IL-lra (1:25)6 10.5 < 0
IL-1 + normal cytosol
+ anti-IL-lra (1:50) 9.4 < 0
IL-1 + normal cytosol
+ anti-TGF3 (1:25)11 0 100%
IL- 1 + normal cytosol
+ anti-TGFB (1:50) 0 100%
IL-1 16.9
IL-I + psoriatic keratome fractions 0 100%
IL-1 + psoriatic cytosol
+ anti-IL-lra (1:25) 28.4 < 0
IL-i + psoriatic cytosol
+ anti-TGFj3 (1:25) 0 100%
* Amount of IL-2 released as detected by 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide reduction by LBRM.33 cells
cultured with a suboptimal concentration of rIL-I (0.25 U/ml) in the
absence or presence ofMono Q fractions containing IL- inhibitory
activity.
* IL-I inhibition by cytosol fractions with or without antibodies is
quantified as percent suppression of IL-2 release induced by 0.25 U/
ml of rIL- 1.
§ Anti-IL-Ira ascites (1.10) was added to the mixture of IL-1, Mono Q
fractions, PHA, and LBRM.33 cells at a dilution of 1:25.
11 Anti-TFG# ascites (I D. 1 16) was added to the mixture of IL- 1, Mono
Q fractions, PHA, and LBRM.33 cells at a dilution of 1:25.
ized by the mAb to IL-Ira (28.4 U/ml IL-2 release) but, again,
unaffected by the neutralizing antibody to TGF,3. Further evi-
dence that the IL-I inhibitory activity from psoriatic skin was
indeed due to IL-Ira was the complete neutralization of IL- I
inhibitory activity in the major size-fractionated TSK
G2000SW peak (Fig. 4 A) in addition to unfractionated psori-
atic cytosol by the anti-IL-Ira mAb (data not shown).
IL-Ira protein in skin. Although IL-i inhibitory activity
was much more easily demonstrable in psoriatic relative to
normal skin, it was possible that this result might not be due to
increased IL- Ira but to reduced IL- I a. The amounts of IL- Ira
and IL-lIa proteins in samples of unfractionated epidermal cy-
tosols were therefore quantified by specific ELISAs and ex-
pressed per milligram of total protein. Normal skin extracts
contained 73.9±15.6 ng IL-ira/mg protein and 0.6±0.4 ng
IL-la/mg protein (Table II). Uninvolved psoriatic skin exhib-
ited levels of IL-Ira, 78.6+14.6 ng/mg protein, and IL-la,
1.3±1.2 ng/mg protein, that were similar to normal skin. How-
ever, the levels ofboth IL- Ira and IL- Ia were lower in clinically
stable involved psoriatic skin, with IL-Ira present at 53.8±7.2
ng/mg protein and IL-la present at 0.05±0.08 ng/mg protein.
If the relative amounts of IL-Ira to IL-i a are compared for
normal ( 123), uninvolved (60.5), and involved ( 1,076) psori-
atic skin, an approximate 10-fold increase in the amounts of
IL-Ira to IL-i a occurred in involved psoriatic relative to nor-
mal or uninvolved psoriatic epidermis (Table II). Ifthe individ-
ual IL-Ira/IL-la ratios within the three groups are compared,
the increase in the involved psoriatic IL-Ira/IL-i a ratio is sta-
tistically significant upon comparison to normal (P < 0.0004)
or uninvolved (P < 0.0007) epidermis by univariate one-way
analysis of variance of log-transformed data. However, by the
same statistical analysis the individual IL-Ira/IL-lIa ratios of
normal and uninvolved psoriatic epidermis were not statisti-
cally significantly different (P = 0.44).
Epidermal IL-Ira is similar in molecular weight to icIL-
Ira. Based upon size-fractionation chromatography ofhuman
keratome cytosol, the molecular mass of the epidermal IL-Ira
Table IL Elevated IL-ira/IL-Ia Ratios in Keratome Cytosols
Sample IL-i ra (n)* IL-la (n)* IL-ira/IL-lat
ng/mg protein
Normal skin 73.9±15.6 (6) 0.6±0.4 (6) 123
Psoriatic skin,
uninvolved 78.6±14.6 (7) 1.3±1.2 (4) 60.5
Psoriatic skin,
involved 53.8±7.2 (6) 0.05±0.08 (6) 1076
* The concentrations of IL- Ira and IL- I a proteins in keratome cyto-
sols from normal skin, uninvolved psoriatic skin, or involved psoriatic
skin were determined by specific ELISAs. Data is expressed in terms
of ng IL- Ira or IL- la/mg protein. The same samples were analyzed
for each cytokine, except for three samples of psoriatic uninvolved
epidermis that were able to be analyzed for IL-Ira but were of insuf-
ficient volume to be simultaneously analyzed for IL- I a. Data repre-
sent mean±SD based upon the indicated sample numbers (n).
* Ratio of IL- Ira to IL- Ia based upon ng/mg protein of each protein
in the keratome cytosol. Psoriatic involved vs normal, P < 0.0004;
psoriatic involved vs uninvolved, P < 0.0007; psoriatic uninvolved
vs normal P = 0.44 by univariate one-way analysis of variance of
log-transformed data.
576 Hammerberg, Arend, Fisher, Chan, Berger, Haskill, Voorhees, and Cooper








Figure 7. Western blot
analysis of IL- I ra pro-
tein using mAb 1.5. The
arrow indicates the mi-
gration of recombinant
monocyte IL-lra in bar
1. Bar 2 contains cul-
tured keratinocyte ly-
sate, bar 3 involved
psoriatic keratome cyto-
sol, bar 4 normal kera-
tome cytosol, and bar 5
mol wt markers.
would appear to be - 30 kD (Figs. 2 and 5). This is larger than
the 17-kD (nonglycosylated) and 22-25-kD (glycosylated)
sizes reported for the secreted IL-Ira protein obtained from
activated monocytes or the 20-kD intracellular IL-Ira protein
expressed by in vitro-cultured keratinocytes and lung epithelia
(38). A comparison of the sizes of IL-Ira proteins from ex-
tracts of normal cultured keratinocytes and keratome cytosols
was made to recombinant monocyte IL- Ira protein by immu-
noblotting after separation on SDS-PAGE (Fig. 7). The epi-
dermal-derived IL-Ira from both normal and involved psori-
atic skin migrated at 20 kD by SDS-PAGE, the same size as
keratinocyte IL-Ira. Both the epidermal and keratinocyte IL-
Ira protein migrated slightly larger than the recombinant IL-
Ira protein derived from monocytes (secreted IL-Ira), suggest-
ing that IL- I ra protein produced by epidermal keratinocytes in
vivo represents the intracellular splice variant of IL- Ira.
IL-i ra mRNA in normal andpsoriatic skin. To evaluate the
relative expression ofmRNAs for the secreted and intracellular
forms of IL-Ira in normal and involved psoriatic skin, PCR
analysis was performed. Both normal 'and clinically stable in-
volved psoriatic skin expressed mRNA for the intracellular
(Fig. 8 A) and secreted (Fig. 8 B) forms of IL-Ira. However,
1 2 3 4 5 6 7 8
A
B
Figure 8. (A) Intracellu-
lar IL-Ira, (B) secreted
IL-Ira, and (C) IL-1,8
mRNAs as detected by
PCR in normal and
psoriatic keratomes.
Bars 1-4 are the stan-
dard curve, ranging
from 14 to 0.014 pg/ml.
Bar 5 contains total
RNA from 4-h adherent
monocytes, bar 6 non-
adherent monocytes,
bar 7 normal keratome,
and bar 8 psoriatic in-
volved keratome.
only involved psoriatic skin had sufficient mRNA levels for
IL-1:3 as detected by PCR (Fig. 8 C). This is similar to our
previous observation of increased IL-1: mRNA levels in in-
volved psoriatic skin relative to normal skin (30). Monocytes
did not express detectable amounts ofmRNA for the intracel-
lular form of IL- lra (Fig. 8 A), but contained mRNA for both
secreted IL- 1 ra (Fig. 8 B) and IL- 1(3 (Fig. 8 C). Densitometer
readings ofthese gels showed that mRNA levels in both normal
and involved psoriatic skin for intracellular IL-Ira (Fig. 9 A)
were - 10-fold greater than the mRNA levels for secreted IL-
1 ra (Fig. 9 B). These results also indicate that the mRNA levels
for both IL- lra forms were higher in psoriatic involved skin
relative to normal skin. Of note, the mRNA levels of secreted
IL-lra in monocytes (Fig. 9 B) compared with IL-1I3 (Fig. 9 C)
were approximately equal.
Differential expression ofthe IL-Ira molecule in psoriatic
and normal skin. Because our epidermal extracts of keratome
biopsies represent an average value of all epidermal cells, we
next determined whether IL- I ra was preferentially expressed in
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Figure 9. Amount ofcDNA present in PCR products shown in Fig. 8.
Densitometer readings were performed upon each sample and the
appropriate cDNA standard curve. Based upon the standard curve
the amount ofcDNA in each reverse-transcribed sample was deter-
mined and expressed in pg/jil. Intracellular IL-Ira, secreted IL-Ira,
and IL- 1I values are given in A, B, and C, respectively.
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Figure 10. Localization of IL-Ira protein in normal and psoriatic skin by indirect immunofluorescence. Normal skin reacted with (A) anti-IL-Ira
mAb 1.4 or (B) 1.4 preincubated with soluble recombinant IL-Ira. Psoriatic involved skin stained with (C) 1.4 or (D) 1.4 preincubated with
soluble recombinant IL-Ira. Psoriatic uninvolved skin stained with (E) 1.4 or (F) I.4 preincubated with soluble recombinant IL-Ira (original
magnification X50).
Figure 10 (Continued)
mAbs 1.4 or I.10 against normal epidermis resulted in heavy
staining of the cytoplasm of keratinocytes located in the stra-
tum granulosum but in minimal staining ofthe basal and mid-
epidermis (Fig. 10 A). This reactivity could be absorbed by
preincubation with soluble recombinant IL-lra (Fig. 10 B).
This layer ofthe epidermis is associated with the expression ofa
number of genes associated with terminal differentiation of
keratinocytes. In contrast to the stratum granulosum staining
of normal skin, the greatest intensity of staining by 1.4 against
epidermis from clinically stable psoriatic lesions occurred in
the basal-midbasal layers (Fig. 10 C). In lesional psoriatic
skin, these compartments contain not only an increased popu-
lation of cells in cell cycle, but also undergo accelerated differ-
entiation as indicated by their expression ofgenes not normally
expressed until the stratum granulosum (47, 48).
When the anti-IL- lra mAb I.4 was reacted with epidermis
from uninvolved psoriatic skin, a reactivity pattern interme-
diate between normal and involved psoriatic skin was observed
(Fig. 10 E). Heavy staining was observed in both differentiat-
ing midepidermal cells and basal cells, as well as in basal cells of
the elongated rete pegs and papillary tips. As occurred in nor-
mal epidermis, preincubation ofthemAb with soluble recombi-
nant IL-l ra blocked the reactivity patterns observed in psori-
atic involved (Fig. 10 D) or uninvolved (Fig. 10 F) epidermis.
Nonspecific staining of the stratum corneum in psoriatic in-
volved and uninvolved skin was revealed by the inability of
soluble recombinant IL- lra to block this staining (Fig. 10, D
and F) and by visualization of an identical staining pattern
using the MOPC 21 isotype control antibody (data not
shown). Ofadditional note was the occurrence of unidentified
dermal cells in lesional psoriatic skin that express IL- Ira (Fig.
10 C).
Discussion
The results ofour studies indicate that IL- 1 ra is present in both
normal and psoriatic epidermis. The epidermal IL- 1ra had a
molecular mass of20 kD by SDS-PAGE and an apparent mo-
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lecular mass of 30 kD by gel-filtration chromatography, likely
because ofthe tendency ofsilica-based columns to retard move-
ment of hydrophobic proteins such as IL- 1. Although other
keratinocyte-derived inhibitors of IL- 1 activity have been de-
scribed, (49, 50) their size (40 and 50 kD [49, 50], respec-
tively) and more basic pI (8.8) (49) distinguish them from the
IL- 1 ra activity described here. The size ofthe protein, as deter-
mined by SDS-PAGE, would indicate that epidermal IL- 1 ra is
similar to the intracellular IL-lra produced by cultured kera-
tinocytes (38) and is slightly larger than the 1 7-kD nonglycosy-
lated form ofmonocyte IL- lra (32, 33, 38). However, extracel-
lular monocyte-derived IL- lra is primarily in the 22-25-kD
glycosylated form (32, 33). The absence of this size form in
keratinocyte lysates or conditioned media (39) or in epidermal
keratome cytosols as shown in these studies suggests that epi-
dermal IL- I ra is not glycosylated to any significant degree. Fur-
thermore, the absence ofthe coding region for a leader peptide
in the cDNA sequence for intracellular IL- lra would predict
that this molecule would remain inside the cells; indeed this
molecule is not detected in the medium of cultured keratino-
cytes untreated or treated with UV light (100 mJ/cm2) (not
shown).
PCR analysis revealed the presence in normal skin of
mRNAs for both the monocyte and keratinocyte variants of
IL- 1 ra. Both forms were also present in involved psoriatic epi-
dermis, although in greatly increased amounts and with the
mRNA for the keratinocyte variant of IL- lra exceeding by a
factor of 10 the mRNA for the monocyte form. However, given
the possible problems with using PCR to quantitate mRNA
these numbers should not be taken as absolute. Since cultured
keratinocytes contain only the mRNA for the intracellular
form of IL-lra (38), the mRNA for the monocyte variant
found in the epidermis by PCR may be derived from Langer-
hans or other cells. That the 1 7-kD monocyte-derived protein
was not found in normal or psoriatic keratome cytosols by
Western blot analysis may be due to the relative insensitivity of
this technique. Alternatively, themRNA for the monocyte vari-
ant of IL- 1ra may be present in skin with little to no protein
translated. The in situ immunofluorescence staining of IL- 1 ra
protein did not resolve the differences in sIL- 1 ra expression
obtained by Western blot analysis and PCR analysis, since the
antibodies recognize a common sequence and cannot distin-
guish between the two forms.
The overall IL- 1 ra levels were lower in psoriatic epidermis
from clinically stable plaques as compared with normal epider-
mis. However, the decrease in psoriatic IL- 1 ra levels was not as
extreme as that observed for IL- 1a (30), resulting in a 10-fold
increase in the amount of IL- I ra relative to IL- I a in psoriatic
lesions compared with normal skin (P < 0.0004). The epider-
mal IL-Ira levels may represent both the monocyte and kera-
tinocyte variants of this molecule. Antisera are not yet avail-
able to discriminate between these two forms of IL- 1ra. An-
other major difference between psoriatic and normal epidermis
is the location of the IL- 1 ra protein as revealed by indirect
immunofluorescence. IL- 1 ra protein in normal epidermis is
localized predominantly in the stratum granulosum. In psori-
atic epidermis from clinically stable plaques, the intense band
of IL- 1ra staining in the granular layer disappears and is re-
placed with a more homogeneous staining pattern in the squa-
mous cell and granular layers. In addition, the psoriatic lesions
showed increased presence of IL- 1 ra protein in the basal to
midbasal layers. This pattern resembles changes in differentia-
tion that have been reported for involucrin and transglutamin-
ase in epidermal cells in vivo. These molecules are normally
expressed in the more differentiated cells ofthe stratum granu-
losum but in psoriasis are present in cells above the basal layer
(47, 48, 51). IL- 1 a, the IL-l molecule that is present in the
highest amount in the epidermis (30), has also been detected
throughout the epidermis (52). However, IL- 1 a may be com-
partmentalized to a region of normal epidermis reciprocal to
IL-l ra, as polyclonal anti-IL- 1 a antibodies preferentially react
with the basal cell layer (53).
The increased expression of IL- 1 ra protein in the lower lev-
els of lesional psoriatic epidermis may represent activation of
IL- 1 ra in concert with other terminal differentiation-asso-
ciated proteins. The signals that induce accelerated terminal
differentiation and epidermal growth in clinically stable lesions
of psoriasis are increasingly being attributed to cytokines re-
leased as a result of immune activation of cells (54-58). In-
creased numbers (22, 23, 59) and activity (55-58, 60) of skin-
infiltrating T lymphocytes, antigen-presenting cells (24, 61),
cytokines (62, 63), phospholipase C/protein kinase C-me-
diated cellular signals (64), and growth factors (54, 65) have
been implicated in the maintenance of the characteristic fea-
tures of this disease. In addition, these factors may influence
the altered epidermal differentiation (47, 48, 66, 67) and the
increased keratinocytic, endothelial, and dendritic cell prolifer-
ation characteristic of psoriatic lesions (25-27).
Alternatively, increased expression of the intracellular IL-
1 ra protein may be a driving force for altered keratinocyte dif-
ferentiation in psoriasis. The intracellular nature of both the
IL-lra protein (38) and IL-la and IL-I13 (13) produced by
epidermal cells suggests that the IL-lra protein may play an
intracellular role in regulating keratinocyte responses to cyto-
plasmic constitutively produced IL-1. This regulation may
even be occurring in the nucleus because IL-1 has been de-
tected in the nucleus of keratinocytes (30). Haskill et al. (38)
proposed that the intracellular IL- Ira may antagonize IL-I by
binding to IL-I receptors possibly present on the nuclear mem-
brane (68).
The involvement of IL-I in regulating keratinocyte growth
is controversial, with either potentiating (20) or inhibitory ef-
fects (69) being observed when IL-I is incubated with cultured
human keratinocytes. The discrepancy between these observa-
tions could be due to differences in culture conditions. Ristow
(29) showed that IL- 1 alone is not directly mitogenic for kera-
tinocytes, but, in the in vivo milieu of multiple cytokines and
growth factors, extracellular IL-I does appear to be a growth
promoter. Varying the concentration of intracellular (keratin-
ocyte) IL- Ira relative to IL-I in keratinocytes may provide an
additional level of control of keratinocyte growth. An imbal-
ance in the icIL- Ira/IL-I a ratio could be another exacerbating
factor resulting in the maintenance of the hyperproliferative
state or accelerated differentiation ofkeratinocytes in clinically
stable psoriatic plaques.
In conclusion, we demonstrated that normal human epi-
dermis constitutively produces an IL-I inhibitor and that this
inhibitor is identical to a mRNA splicing variant (38) of the
monocyte-derived IL-I receptor antagonist cloned by Eisen-
berg et al. (34) and Carter et al. (33). This variant lacks a leader
sequence for secretion (38) and thereby resides intracellularly
in unperturbed human epidermis, predominantly in cells un-
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dergoing terminal differentiation in the stratum granulosum.
Our initial finding that an IL- I inhibitory bioactivity was ele-
vated in clinically stable psoriatic epidermis can now be ac-
counted for by the observations that this activity represents
intracellular IL- 1 ra protein expressed aberrantly in lower layers
of lesional epidermis in association with markedly decreased
IL- 1 a levels. Understanding the events leading to alterations in
the ratio of IL- lra and IL-I in cells as well as the functional
consequences of such alterations will yield important informa-
tion on intracellular effects of such potent cytokines as IL- 1.
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